#Pharma #Biotech #ObesityTreatment #ClinicalTrials To view or add a comment, sign in Pfizer breaks into obesity market in China with approval for Sciwind-partnered GLP-1 Less than two weeks after Pfizer struck a deal with Sciwind Biosciences to gain commercial rights to a GLP-1 drug, Chinas National Medical Products Administration (NMPA) has approved the treatment for patients with obesity
Development of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Obesity Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide and semaglutide, were initially developed for the treatment of type 2 diabetes but were found to be effective not only in reducing blood glucose levels but body weight as well [18,19,20]
By calling these products GLP-1 patches, companies create the illusion that they are linked to GLP-1 science
Once released into the bloodstream, GLP-1 acts as a hormone to influence multiple organs and systems throughout the body
Targeted oral peptide delivery using multi-unit particulates: Drug and permeation enhancer layering approach
Therapies like Semaglutide and Tirzepatide work best when combined with healthy habits
:format(webp))
